In particular, inhibition of ANGPTL3 by siRNA may be a future panacea against hypertriglyceridemia in a variety of dyslipidemia conditions,181 including residual LDL‐C elevation in FH.135, 166, 182. This evidence concerns the gene ANGPTL3 and metabolic syndrome.